Robert Hoffman

Robert E.
Hoffman is currently Director at Day For Change, Independent Director at FibroBiologics, Inc. starting 2025, Director at TuHURA Biosciences, Inc. starting 2024, and Chief Financial & Accounting Officer at CytoDyn, Inc. starting 2025.
Former roles include Chairman, President, Chief Executive Officer & CFO at Kintara Therapeutics, Inc. from 2023 to 2024; Chairman at Antibe Therapeutics, Inc. from 2022 to 2024; Independent Director at Saniona AB from 2021 to 2022; Chief Financial Officer & Senior VP-Finance at Heron Therapeutics, Inc. from 2017 to 2020; Independent Director at Kura Oncology, Inc. from 2015 to 2021; Chief Financial Officer at AnaptysBio, Inc. from 2015 to 2016; Chief Financial & Accounting Officer, Executive VP at Innovus Pharmaceuticals, Inc. from 2016 to 2017; Independent Director at MabVax Therapeutics Holdings, Inc. from 2014 to 2017; Independent Director at CombiMatrix Corp.
from 2013 to 2017; President & Director at Financial Executives International of San Diego Chapter from 2010 to 2020; Chief Financial Officer at Polaris Group, Inc. in 2011; Chief Financial Officer & Senior VP-Finance at Arena Pharmaceuticals, Inc. from 2012 to 2015; Assistant Controller at Document Sciences Corp.
from 1994 to 1997; and Director or Independent Director roles at Telik, Inc., Zeta Acquisition Corp.
III, Aslan Pharmaceuticals Ltd., Versartis, Inc., ASLAN Pharmaceuticals Pte Ltd., and Esperion Therapeutics, Inc. Education includes an undergraduate degree from St. Bonaventure University conferred in 1988.